Kedokteran & Kesehatan editorial
Open AccessOA2022
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
The CHRONOS trial shows that ctDNA-based screening can identify patients with RAS/BRAF/EGFR mutations who are unlikely to benefit from anti-EGFR rechallenge, and that those without such mutations can achieve meaningful response rates with panitumumab.
A. Sartore-Bianchi; F. Pietrantonio; S. Lonardi; Benedetta Mussolin; F. Rua; Giovanni Crisafulli; Alice Bartolini; E. Fenocchio; A. Amatu; P. Manca; F. Bergamo; F. Tosi; G. Mauri; M. Ambrosini; F. Daniel; V. Torri; A. Vanzulli; D. Regge; G. Cappello; C. Marchiò; E. Berrino; A. Sapino; S. Marsoni; S. Siena; A. Bardelli· Nature Medicine· 2022· DOI 10.1038/s41591-022-01886-0
The core problem
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. The CHRONOS trial (ClinicalTrials.gov: NCT03227926; EudraCT 2016-002597-12) was designed to test this hypothesis.
Innovation
CHRONOS was an open-label, single-arm phase 2 clinical trial exploiting blood-based identification of RAS/BRAF/EGFR mutations levels to tailor a chemotherapy-free anti-EGFR rechallenge with panitumumab. Patients with tissue-RAS WT tumors after a previous treatment with anti-EGFR-based regimens underwent an interventional ctDNA-based screening. Of 52 patients, 16 (31%) carried at least one mutation conferring resistance to anti-EGFR therapy and were excluded. The primary endpoint was objective response rate. Secondary endpoints were progression-free survival, overall survival, safety and tolerability of this strategy.
Introduction
Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are approved for the treatment of RAS wild-type (WT) metastatic colorectal cancer (mCRC), but the emergence of resistance mutations restricts their efficacy. We previously showed that RAS, BRAF and EGFR mutant alleles, which appear in circulating tumor DNA (ctDNA) during EGFR blockade, decline upon therapy withdrawal. We hypothesized that monitoring resistance mutations in blood could rationally guide subsequent therapy with anti-EGFR antibodies. The CHRONOS trial (ClinicalTrials.gov: NCT03227926; EudraCT 2016-002597-12) was designed to test this hypothesis.
Why it matters
The CHRONOS trial demonstrates that interventional liquid biopsies can be effectively and safely exploited in a timely manner to guide anti-EGFR rechallenge therapy with panitumumab in patients with mCRC. The results show that ctDNA monitoring can identify patients who are likely to benefit from rechallenge and exclude those with resistance mutations. Further larger and randomized trials are warranted to formally compare panitumumab rechallenge with standard-of-care therapies in this patient setting.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member content…